Real-time Quotes | Nasdaq Last Sale

Closed 16:00 11/27 EST
Corp Actions
Biocept's assays viable and sensitive for detecting tumor cells and biomarkers
Biocept (BIOC) +2% in premarket, after announcing results of a study analyzing cerebrospinal fluid ((CSF)) samples in patients with primary lung or breast cancer with either brain or leptomeningeal disease.The findings indicate
Seekingalpha · 11/20 14:02
Study Shows Biocept's Assays are Viable and Sensitive for Detecting Tumor Cells and Biomarkers in the Cerebrospinal Fluid of Patients with Breast and Lung Cancer that has Metastasized to the Central Nervous System
PR Newswire · 11/20 13:00
Biocept To Present Results From Study Using Biocept's Target Selector Testing To Monitor Breast Cancer Dec. 9
SAN DIEGO, Nov. 17, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ:BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable
Benzinga · 11/17 13:07
Results from Study Using Biocept's Target Selector™ Testing to Monitor Breast Cancer Disease Progression to be Presented at 2020 SABCS®
Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces that results from a prospective study using Target Selector™ testing to monitor disease progression in patients with metastatic breast cancer will be featured in a poster presentation at the virtual 2020 San Antonio Breast Cancer Symposium® (SABCS) on December 9, 2020.
PR Newswire · 11/17 13:05
Is Biocept Stock a Buy Right Now? This Is What You Need to Know
Last week was quite a roller-coaster ride for Biocept (BIOC) investors. On Thursday, shares of the microcap molecular oncology diagnostics company rocketed 25%, delivering shareholders windfall profits after Biocept announced that it has now received more than 100,000 patient samples to process for COVID-19 testing through its RT-PCR (reverse transcription polymerase chain reaction) machines.Committing to "providing this important service during the pandemic and we continue to return the vast majority of COVID-19 test results to our customers within 48 hours of receiving a sample," Biocept regaled investors with tales of how "COVID-19 RT-PCR testing will have a significant positive impact on our revenues through the remainder of the year and continuing into 2021."But then the closing bell struck, and Biocept reported its actualfinancial results for Q3 2020 -- a net loss of $4.9 million. By the time investors finished digesting that number, Biocept stock had given back all of the gains its stock had made earlier in the day, and more. Although the stock fell "only" 22% Friday, this percentage decline, times a bigger stock price, left Biocept stock trading below Wednesday's closing price at just $4.78 a share.But were the results really that bad? Not according to Maxim analyst Jason McCarthy, they weren't. Biocept, noted McCarthy, reported Q3 revenues up 400% year over year at $6.6 million. True, Biocept lost money for the quarter. But its $4.9 million net loss worked out to only $0.43 per share -- four cents better than the $0.47 loss per share that analysts, on average, had expected.And in McCarthy's view, COVID-19 testing will indeed be the growth driver than Biocept envisions. $5.7 million of the $6.6 million in revenue recorded in the quarter, after all, came from Covid testing, and that was enough to more than make up for "temporary" revenue declines in oncology testing that were "due to the pandemic" -- and at positive gross margins to boot.Every time Biocept tests a sample for Covid, notes McCarthy, it collects a $100 "reimbursement."  And "COVID testing is... continuing to grow," says the analyst, "with the number of samples more than doubling each month over 3Q20."McCarthy predicts that this growth trend will continue, "as Biocept has received approximately as many samples in 4Q20 to date as they received in all of 3Q20." (Hint: Q3 ended on Sept. 30. It's Nov. 15 as I type this note -- so 1.5 months of Q4 have seen Biocept collect as many $100-samples as it did in three months of Q3: a 100% growth rate).Biocept collected "30K samples in September alone," by they way, says McCarthy -- $3 million when translated into revenues.  If samples keep arriving at the rate they are currently -- much less double -- that would seem to imply at least $9 million in Covid testing revenue in Q4. For the record, McCarthy is only modeling for $11.4 million, plus about $900,000 in other revenues, so a total of $12.3 million. But other Wall Street analysts on average have Biocept down for just $3.5 million in revenue this quarter.If McCarthy's right, Biocept could end up blowing that estimate entirely out of the water -- and Q4 could be a real blowout of an earnings surprise.To this end, McCarthy doubles down on his "buy" recommendation on Biocept stock, and his $200 price target, too. (To watch McCarthy's track record, click here)It has been relatively quiet when it comes to other analyst activity. In the last three months, only 2 analysts have issued ratings. However, as they were both Buys, the word on the Street is that BIOC is a Moderate Buy . Based on the $7 average price target, shares could climb 11% higher in the next twelve months. (See BIOC stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
TipRanks · 11/16 23:47
Microcaps mostly among midday movers
Gainers: Urovant Sciences Ltd. (UROV) +94%.CBAK Energy Technology, Inc. (CBAT) +68%.Asia Pacific Wire & Cable Corporation Limited (APWC) +63%.National Holdings Corporation (NHLD) +46%.Electrameccanica Vehicles Corp. (SOLO) +35%.Polar Power, Inc. (POLA)
Seekingalpha · 11/13 18:15
Urovant Sciences, Zomedica leads healthcare gainers; Cassava Sciences, Allied Healthcare Products among major losers
Gainers: Urovant Sciences (UROV) +94%, Zomedica (ZOM) +35%, Ovid Therapeutics (OVID) +16%, Fulgent Genetics (FLGT) +12%, Myovant Sciences (MYOV) +11%.Losers: Cassava Sciences (SAVA) -26%, Allied Healthcare Products (AHPI) -24%, Biocept (BIOC) -19%, Zhongchao (ZCMD) -14%, IMAC Holdings (IMAC) -14%.
Seekingalpha · 11/13 16:03
American Well, BigCommerce Holdings leads premarket losers' pack
Cassava Sciences (SAVA) -18% after announcing proposed public offering.Shift Technologies (SFT) -18% on Q3 earnings release.IMAC Holdings (IMAC) -17%.EuroDry (EDRY) -15%.Biocept (BIOC) -15% on Q3 earnings release.Creative Realities (CREX) -12% on Q3 earnings release.Zhongchao (ZCMD) -12%.Allied Healthcare Products
Seekingalpha · 11/13 13:26
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BIOC. Analyze the recent business situations of Biocept through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts


Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BIOC stock price target is 20.00 with a high estimate of 20.00 and a low estimate of 20.00.
Institutional Holdings
Institutions: 37
Institutional Holdings: 1.12M
% Owned: 8.38%
Shares Outstanding: 13.40M
Sold Out
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Medical Equipment, Supplies & Distribution
Healthcare Equipment & Supplies
Key Executives
Non-Executive Chairman
David Hale
President/Chief Executive Officer/Director
Michael Nall
Chief Financial Officer/Senior Vice President/Secretary
Timothy Kennedy
Senior Vice President/Chief Scientific Officer
Lyle Arnold
Senior Vice President
Cory Dunn
Senior Vice President
Michael Terry
Vice President/Director of Sales
Scott Nicholson
Samuel Riccitelli
Independent Director
Marsha Chandler
Independent Director
Bruce Gerhardt
Independent Director
Bruce Huebner
Independent Director
Ivor Royston
Independent Director
Margaret Faye Wilson
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BIOC
Biocept, Inc. is a molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.
Hot Stocks

Webull offers kinds of Biocept Inc stock information, including NASDAQ:BIOC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIOC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BIOC stock methods without spending real money on the virtual paper trading platform.